Karyopharm Therapeutics Inc (KPTI) support and resistance · rev $68.5M
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
This page maps Karyopharm Therapeutics Inc (KPTI) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
KPTI currently screens at market cap $205.6M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new KPTI 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the KPTI quote page for the session range and the stock page for the full model.
Not investment advice.